Policy, trade, and security are prompting proactive moves to the U.S. — before capacity tightens.
Biologics manufacturing is being reshaped by a new mix of policy, trade, and security pressures. What once felt like a stable global supply network is now influenced by legislation including the BIOSECURE Act, talk of tariffs on drugs manufactured outside the U.S., evolving security scrutiny, and the lingering supply chain fragility revealed during COVID-19. Investors, boards, and regulators are now asking harder questions about supply chain, data security, and speed to market.
From our perspective as a United States contract development and manufacturing organization (CDMO), we have been seeing a clear shift: drug developers aren’t waiting for disruption to hit. They are conducting early risk assessments, onshoring programs, and locking in U.S. capacity strategically rather than reactively.
In this whitepaper, we explore seven forces reshaping global biologics manufacturing: policy risk, geopolitical tension, trade and tariff volatility, regulatory access, IP and data security, operational complexities, and supply chain fragility. Drawing on lessons from recent technology transfers, we see how forward-looking companies are future-proofing their pipelines before U.S. capacity tightens and market conditions force rushed moves.